Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7JXZ

Structure of HbA with compound (S)-4

7JXZ の概要
エントリーDOI10.2210/pdb7jxz/pdb
分子名称Hemoglobin subunit alpha, Hemoglobin subunit beta, PROTOPORPHYRIN IX CONTAINING FE, ... (8 entities in total)
機能のキーワードhemoglobin, oxygen transport
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数4
化学式量合計66829.56
構造登録者
Jasti, J. (登録日: 2020-08-28, 公開日: 2021-01-13, 最終更新日: 2023-10-18)
主引用文献Gopalsamy, A.,Aulabaugh, A.E.,Barakat, A.,Beaumont, K.C.,Cabral, S.,Canterbury, D.P.,Casimiro-Garcia, A.,Chang, J.S.,Chen, M.Z.,Choi, C.,Dow, R.L.,Fadeyi, O.O.,Feng, X.,France, S.P.,Howard, R.M.,Janz, J.M.,Jasti, J.,Jasuja, R.,Jones, L.H.,King-Ahmad, A.,Knee, K.M.,Kohrt, J.T.,Limberakis, C.,Liras, S.,Martinez, C.A.,McClure, K.F.,Narayanan, A.,Narula, J.,Novak, J.J.,O'Connell, T.N.,Parikh, M.D.,Piotrowski, D.W.,Plotnikova, O.,Robinson, R.P.,Sahasrabudhe, P.V.,Sharma, R.,Thuma, B.A.,Vasa, D.,Wei, L.,Wenzel, A.Z.,Withka, J.M.,Xiao, J.,Yayla, H.G.
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
J.Med.Chem., 64:326-342, 2021
Cited by
PubMed Abstract: Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation (β6 Glu → Val) on the β-chain of adult hemoglobin (HbA) that results in sickled hemoglobin (HbS). In the deoxygenated state, polymerization of HbS leads to sickling of red blood cells (RBC). Several downstream consequences of polymerization and RBC sickling include vaso-occlusion, hemolytic anemia, and stroke. We report the design of a noncovalent modulator of HbS, clinical candidate PF-07059013 (). The seminal hit molecule was discovered by virtual screening and confirmed through a series of biochemical and biophysical studies. After a significant optimization effort, we arrived at , a compound that specifically binds to Hb with nanomolar affinity and displays strong partitioning into RBCs. In a 2-week multiple dose study using Townes SCD mice, showed a 37.8% (±9.0%) reduction in sickling compared to vehicle treated mice. (PF-07059013) has advanced to phase 1 clinical trials.
PubMed: 33356244
DOI: 10.1021/acs.jmedchem.0c01518
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.23 Å)
構造検証レポート
Validation report summary of 7jxz
検証レポート(詳細版)ダウンロードをダウンロード

227561

件を2024-11-20に公開中

PDB statisticsPDBj update infoContact PDBjnumon